✦ LIBER ✦

EVALUATION OF CARDIAC FUNCTION IN SYMPTOMATIC HEART FAILURE PATIENTS IN A SINGLE INFUSION, PHASE 1, DOSE ESCALATION STUDY OF GLIAL GROWTH FACTOR 2

✍ Scribed by Brittain, Evan; Muldowney, James; Geisberg, Carrie; Caggiano, Anthony; Eisen, Andrew; Anderson, Sarah; Sawyer, Douglas; Mendes, Lisa; Lenihan, Daniel

Book ID: 122598544
Publisher: Elsevier Science
Year: 2013
Tongue: English
Weight: 288 KB
Volume: 61
Category: Article
ISSN: 1558-3597
DOI: 10.1016/S0735-1097(13)60715-9

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

SAFETY AND TOLERABILITY OF GLIAL GROWTH

SAFETY AND TOLERABILITY OF GLIAL GROWTH FACTOR 2 IN PATIENTS WITH CHRONIC HEART FAILURE: A PHASE I SINGLE DOSE ESCALATION STUDY

✍ Lenihan, Daniel J.; Anderson, Sarah; Geisberg, Carrie; Caggiano, Anthony; Eisen, 📂 Article 📅 2013 🏛 Elsevier Science 🌐 English ⚖ 151 KB

Intracoronary basic fibroblast growth fa

Intracoronary basic fibroblast growth factor (FGF-2) in patients with severe ischemic heart disease: results of a Phase I open-label dose escalation study

✍ Roger J Laham; Nicholas A Chronos; Marilyn Pike; Mark E Leimbach; James E Udelso 📂 Article 📅 2000 🏛 Elsevier Science 🌐 English ⚖ 339 KB

A Phase 1–2 Dose-Escalating Study Evalua

A Phase 1–2 Dose-Escalating Study Evaluating the Safety and Tolerability of Istaroxime and Specific Effects on Electrocardiographic and Hemodynamic Parameters in Patients with Chronic Heart Failure with Reduced Systolic Function

✍ Jalal K. Ghali; William B. Smith; Guillermo Torre-Amione; William Haynos; Barry 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 963 KB

A phase 1 study of weekly dosing of tras

A phase 1 study of weekly dosing of trastuzumab emtansine (T-DM1) in patients with advanced human epidermal growth factor 2–positive breast cancer

✍ Muralidhar Beeram; Ian E. Krop; Howard A. Burris; Sandhya R. Girish; Wei Yu; Mic 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 English ⚖ 417 KB

A phase I dose escalation study of BIBW

A phase I dose escalation study of BIBW 2992, an irreversible dual inhibitor of epidermal growth factor receptor 1 (EGFR) and 2 (HER2) tyrosine kinase in a 2-week on, 2-week off schedule in patients with advanced solid tumours

✍ Eskens, F A L M; Mom, C H; Planting, A S T; Gietema, J A; Amelsberg, A; Huisman, 📂 Article 📅 2007 🏛 Nature Publishing Group 🌐 English ⚖ 173 KB

Rationale and Design for a Phase II Stud

Rationale and Design for a Phase II Study Evaluating the Effect of the Cardiac Myosin Activator, CK-1827452, on Cardiac Function, Hemodynamics, and Myocardial Oxygen Consumption in Patients with Heart Failure

✍ J.D. Parker; A.D. Michaels; D.A. Kass; A.A. Wolff; G.M. Felker; F.I. Malik 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 110 KB